Artivion Inc. Common Stock (AORT)
Stock · NYSE · Health Care
$21.71as of 10/16/2026
Price chart
Active signals
AORT Signal Track Record
How signals performed across all stocks →What AORT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | +0.2% | 53% | September 15, 2026 |
| Bollinger Band Breakout | 26 | +0.2% | 50% | July 28, 2026 |
| Bollinger Band Breakdown | 21 | -0.1% | 48% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +8.3% | 75% | October 5, 2023 |
| Any 20-session window (baseline) | +1.5% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AORT
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXU…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 1,800
- Website
- artivion.com/
Fundamentals
- 1-day range
- $21.64$22.37
- Market cap
- $1.29B
- P/E (trailing)
- 117.64
- P/E (forward)
- 29.10
- EPS (trailing)
- $-0.07
- Dividend yield
- —
- Beta
- 1.30
- Avg. volume
- 638.1K
- Ex-dividend date
- December 9, 2015
How Artivion Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Artivion Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AORTArtivion Inc. Common Stock$21.78▼ 0.41%Market cap $1.29BP/E 117.64$19.16$48.25
- TNDMTandem Diabetes Care Inc. Common Stock$16.24▼ 1.69%Market cap $1.29BP/E —$12.26$29.65
- IARTIntegra LifeSciences Holdings Corporation Common Stock$13.21▼ 2.37%Market cap $1.33BP/E —$8.7$20.49
- BVSBioventus Inc. Class A Common Stock$13.3▼ 3.69%Market cap $1.17BP/E 21.32$6.46$15.89
- IRMDiRadimed Corporation Common Stock$88.27▼ 1.23%Market cap $1.17BP/E 49.82$71.34$107.9
- ATECAlphatec Holdings Inc. Common Stock$10.46▼ 4.30%Market cap $1.42BP/E —$6.82$23.29
- DRTSAlpha Tau Medical Ltd. Ordinary Shares$12.29▼ 6.61%Market cap $1.14BP/E —$3.43$15.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AORT Artivion Inc. Common Stock | $1.29B | 117.64 | $21.78 | ▼ 0.41% | $19.16$48.25 |
| TNDM Tandem Diabetes Care Inc. Common Stock | $1.29B | — | $16.24 | ▼ 1.69% | $12.26$29.65 |
| IART Integra LifeSciences Holdings Corporation Common Stock | $1.33B | — | $13.21 | ▼ 2.37% | $8.7$20.49 |
| BVS Bioventus Inc. Class A Common Stock | $1.17B | 21.32 | $13.3 | ▼ 3.69% | $6.46$15.89 |
| IRMD iRadimed Corporation Common Stock | $1.17B | 49.82 | $88.27 | ▼ 1.23% | $71.34$107.9 |
| ATEC Alphatec Holdings Inc. Common Stock | $1.42B | — | $10.46 | ▼ 4.30% | $6.82$23.29 |
| DRTS Alpha Tau Medical Ltd. Ordinary Shares | $1.14B | — | $12.29 | ▼ 6.61% | $3.43$15.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Transcript: Artivion Q2 2026 Earnings Conference Callbenzinga · 10/12/2026
- 1 Small-Cap Stock with Exciting Potential and 2 We Turn DownYahoo · 10/8/2026
- 1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing HeadwindsYahoo · 10/5/2026
- 2 Growth Stocks with All-Star Potential and 1 We Find RiskyYahoo · 9/25/2026
- 3 Healthcare Stocks We’re Skeptical OfYahoo · 9/23/2026
- Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line ProblemYahoo · 9/16/2026
- 3 Profitable Stocks We Approach with CautionYahoo · 9/11/2026
Insider Activity
Insider Actions →- GREEN ANDREW M · September 10, 2026 · Sale11.5K @ $24.97
- GREEN ANDREW M · September 3, 2026 · Sale1.5K @ $26.02
- GREEN ANDREW M · September 2, 2026 · Sale6.5K @ $27.27
- Mackin James P · August 19, 2026 · Sale70.0K @ $28.96
- GREEN ANDREW M · August 14, 2026 · Sale616 @ $28.55
- Berry Lance A · August 14, 2026 · Sale715 @ $28.55
- Holloway Jean F · August 12, 2026 · Sale977 @ $28.49
- GREEN ANDREW M · June 11, 2026 · Option Exercise30.0K @ $11.03
- GREEN ANDREW M · June 11, 2026 · Option Exercise14.0K @ $18.44
- GREEN ANDREW M · June 11, 2026 · Sale30.0K @ $20.69
- GREEN ANDREW M · June 11, 2026 · Sale14.0K @ $20.71
- SEMEDO ANTHONY B. · June 2, 2026 · J6.3K
- Salveson Jon W · May 18, 2026 · Grant7.6K
- Burbank Jeffrey H · May 18, 2026 · Grant7.6K
- BEVEVINO DANIEL J · May 18, 2026 · Grant7.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 42.93M
- Total value held
- $1.53B
- Institutional holders
- 232
- Unknown6.47M
- Unknown2.58M
- Unknown2.46M
- Unknown2.27M
- Unknown1.95M
- Unknown1.68M
- Unknown1.64M
- Unknown1.21M
- Unknown1.19M
- Unknown1.18M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Artivion Q2 2026 Earnings Call Transcript Released
Artivion has released the transcript for its Q2 2026 earnings conference call, providing detailed insights into recent performance. The stock is currently trading near its 52-week low, reflecting a significant decline from its high. Analysts maintain a higher average price target, suggesting a gap between current market sentiment and long-term expectations.
Artivion Q2 2026 Earnings Call Transcript Released. Artivion has released the transcript for its Q2 2026 earnings conference call, providing detailed insights into recent performance. The stock is currently trading near its 52-week low, reflecting a significant decline from its high. Analysts maintain a higher average price target, suggesting a gap between current market sentiment and long-term expectations.